Axilea LLC offers innovative microparticle-based vaccines that can be administered via spray, oral, or in ovo methods. These vaccines are easy to mass produce, environmentally friendly, and do not require cold storage, making them ideal for scalable poultry vaccination.
Axilea LLC presents a cutting-edge solution for efficient and scalable vaccination in poultry using microparticle-based vaccines. These vaccines are designed to be administered via spray, oral, or in ovo methods, providing flexibility in mass vaccination strategies. The microparticles encapsulate vaccine components and act as adjuvants, ensuring effective immune responses without the need for high doses of additional adjuvants. The vaccines are also drinkable and compatible with subcutaneous injection, offering a robust and versatile vaccination platform.
Key features:
The technology is at TRL 4, indicating that it has been validated in a laboratory setting. Future steps include scaling production, regulatory readiness, and in vivo efficacy testing in poultry to further advance this promising vaccination technology.
Axilea LLC, which operates as ImmunoMetabolix, is a clinical-stage biotechnology company that utilizes a proprietary engineering approach to develop metabolically-fit immunotherapies. The company focuses on addressing cancer, autoimmune, and inflammatory diseases where existing treatments may be ineffective, costly, or cause significant side effects. By targeting metabolic dysfunctions that can impair the immune system, their core technology, the iMET platform, is designed to generate more potent T-cells capable of specifically killing cancer cells or inhibiting inflammatory processes.
The company's work aims to provide enhanced therapeutic efficacy and patient safety for those suffering from complex immune-related disorders. Originally spun out of research at Arizona State University, the organization works to translate advancements in cell metabolism into actionable healthcare solutions. By focusing on the metabolic fitness of immune cells, the company seeks to offer patients improved outcomes and better quality of life through novel, patient-centric clinical interventions.